Print Share
Content is retrieved from Sharik
17th Dec, 2014
Healthcare Issues
1369 الصحة تسجل دواء «تروليسيتي» للسكري.jpg�

The Ministry of Health has announced that a groundbreaking non-insulin injection for people with Type 2 diabetes now has marketing authorisation. The drug will dramatically improve glycaemic control in patients and effectively slow down the diabetes epidemic.
The injection would only be needed once a week, say medical authorities.
Trulicity, a product by the global US-based pharmaceutical organisation Lilly will be available from the first quarter of 2015 in the UAE.
Dr Amin Hussain Al Amiri, Assistant Undersecretary for Public Health Policy and Licensing in the Ministry of Health, said: “One in 12 people in the world have diabetes with the current global number of diabetics amounting to 375 million. If we do not act fast by 2035 more than 205 million people will be added to the existing population of diabetics worldwide pushing the number to 592 million. Right now a person dies every seven seconds due to diabetic complications and one in two individuals does not know he has diabetes, which is causing more health complications. It is important to support research in this field and the Ministry of Health is the first in this region to register this medicine, which has already been approved by the FDA in the USA and the EU in Europe.”

While the price of the drug has not yet been revealed, Huzur Devletsah, managing director of Lilly, Middle East, said the price would be comparable to existing medication available in the market here.
Providing details of the drug she said: “Trulicity belongs to a category of drugs called glucagon-like peptide (GLP-1) receptor agonists. It acts like the natural hormone GLP-1 helping the body release its own insulin when patients eat, it comes in a ready-to-use pen with a retractable needle.”
Unlike other non-insulin injectables that are known to cause thyroid cancer and pancreatitis, Devletsah assured Gulf News Trulicity was completely safe.
“The most common side effect reported in our trials is mild to moderate nausea when used in combination with insulin injections and low blood sugar. These adverse events are consistent with those seen with other GLP-1 receptor agonists.”

About Diabetes
An estimated 387 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin .

About Trulicity
Trulicity is a once-weekly, glucagon-like peptide-1 (GLP-1) receptor agonist injectable prescription medicine. Trulicity is not insulin. It acts like GLP-1, a natural hormone, helping the body release its own insulin when patients eat. 

Trulicity comes in a prefilled pen. It can be taken any time of day, with or without meals, and should be injected subcutaneously in the abdomen, thigh or upper arm

Did you find this content useful?

You can help us improve by providing your feedback about your experience.